https://biotechmorning.com/news/white-house-veto-power-nih-grants Biotech Morning en 2026-09-22T14:18:18.490Z The White House Wants Veto Power Over Science Funding https://biotechmorning.com/news/alteogen-novartis-3-billion-subcutaneous-delivery-deal Biotech Morning en 2026-09-22T14:17:37.730Z The $3.2 Billion Bet That You'll Never Sit for an IV Again https://biotechmorning.com/news/novo-nordisk-cagrisema-beats-tirzepatide-weight-loss Biotech Morning en 2026-09-22T14:16:49.520Z Novo Nordisk Just Beat the Best Weight-Loss Drug on the Market https://biotechmorning.com/news/roche-obesity-drug-data-lilly-novo-competition Biotech Morning en 2026-09-22T14:16:05.616Z Roche Just Crashed the Obesity Party. Lilly and Novo Should Be Nervous. https://biotechmorning.com/news/grail-galleri-fda-staff-review-no-major-concerns Biotech Morning en 2026-09-22T14:15:22.411Z A Blood Test That Spots 12 Deadly Cancers Just Cleared Its Biggest Hurdle Yet https://biotechmorning.com/news/nvidia-backed-iambic-therapeutics-ipo-filing Biotech Morning en 2026-09-22T14:14:39.480Z Nvidia's Favorite Drug Company Wants to Go Public https://biotechmorning.com/news/china-25-percent-first-in-class-drug-target-2030 Biotech Morning en 2026-09-22T14:13:56.382Z China Wants to Invent 1 in 4 of the World's New Drugs. By 2030. https://biotechmorning.com/news/adhd-drug-nothing-to-do-with-stimulants Biotech Morning en 2026-09-22T14:13:08.202Z The ADHD Drug That Has Nothing to Do With Stimulants https://biotechmorning.com/news/sarepta-worst-week-gene-therapy-playbook Biotech Morning en 2026-09-22T14:12:21.397Z Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook https://biotechmorning.com/news/viking-therapeutics-obesity-data-spooks-lilly-novo Biotech Morning en 2026-09-22T14:11:38.243Z The $4 Billion Biotech That Just Spooked Obesity's Two Kings https://biotechmorning.com/news/novo-nordisk-strategy-reset-job-cuts Biotech Morning en 2026-09-22T14:10:45.746Z Novo Nordisk Just Torched 4,000 Jobs. Wall Street Still Wasn't Impressed. https://biotechmorning.com/news/scholar-rock-apitegromab-sma-muscle-therapy-fda-approval Biotech Morning en 2026-09-21T14:18:08.632Z The Drug That Treats SMA's Muscle Problem, Not Just Its Genetic One https://biotechmorning.com/news/thyroid-trick-bipolar-depression-elunetirom Biotech Morning en 2026-09-21T14:17:24.444Z The Thyroid Trick That Might Crack Bipolar Depression https://biotechmorning.com/news/bms-nvidia-ai-supercomputer-drug-discovery Biotech Morning en 2026-09-21T14:16:40.436Z BMS Just Bought the Biggest AI Supercomputer in Pharma. Now What? https://biotechmorning.com/news/ionis-zilganersen-zanvastro-fda-approval-alexander-disease Biotech Morning en 2026-09-21T14:15:51.081Z The Disease So Rare It Had Zero Treatments. Until Now. https://biotechmorning.com/news/sleep-drug-aces-adhd-test-alkermes-orexin Biotech Morning en 2026-09-21T14:15:05.707Z A Sleep Drug Just Aced an ADHD Test. Wait, What? https://biotechmorning.com/news/beacon-therapeutics-laru-zova-xlrp-pivotal-win Biotech Morning en 2026-09-21T14:14:18.750Z The Gene Therapy That Could Save Sight for a Disease With Zero Treatments https://biotechmorning.com/news/telix-itm-acquisition-radiopharmaceutical-novartis Biotech Morning en 2026-09-21T14:13:38.333Z Telix Just Wrote a $1.6B Check to Pick a Fight With Novartis https://biotechmorning.com/news/keytruda-trodelvy-tnbc-first-line-fda-approval Biotech Morning en 2026-09-21T14:12:43.752Z The Two-Drug Combo That Just Rewrote the Playbook for Breast Cancer's Worst Villain https://biotechmorning.com/news/novo-nordisk-kallyope-non-incretin-obesity-deal Biotech Morning en 2026-09-21T14:11:55.409Z Novo Nordisk Just Bought an Obesity Playbook That Has Nothing to Do With GLP-1